Skip to main content

PHGE

Stock
Health Care
Biotechnology

Performance overview

PHGE Price
Price Chart

Forward-looking statistics

Beta
0.65
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

Company info

SectorHealth Care
IndustryBiotechnology
Employees112
Market cap$24.5M

Fundamentals

Enterprise value$19.6M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity37.93

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$23.03
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$130K
Avg trading volume (10 day)$87K
Put-call ratio—

Macro factor sensitivity

Growth+0.6
Credit+9.0
Liquidity-3.9
Inflation-0.4
Commodities-0.1
Interest Rates+1.5

Valuation

Dividend yield0.00%
PEG Ratio-0.00
Price to sales—
P/E Ratio-0.20
Enterprise Value to Revenue—
Price to book1.88

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day—
Ex. dividend day—

News

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

BiomX (PHGE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Investment Research (April 18, 2025)
Top 3 Health Care Stocks That May Explode In Q3

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `

Benzinga (July 31, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free